Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Post by narmacon Apr 23, 2022 11:26am
213 Views
Post# 34626185

XB3 and its cost in the health care system?

XB3 and its cost in the health care system?Something I always planned on asking DrDR and have missed doing so,,,,is,,,Just what kind of costs are or will be asscitated with this technology?,,,,is there a reluctance from BP to get in waist deep because of the anticipated cost to produce the conjulates and or other. Is there an expected number or a target number if success is met and what might it look like. How much is reasonable in saving a life is an important discussion for all. It has always been in the back of my mind we will most likely be on the high end of the pricing scale in delivering our compounds to patients. Just thinking here. 
<< Previous
Bullboard Posts
Next >>